March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to ...

The partnership focuses on enhancing patient reach for cutting-edge diabetes care and chronic weight management solutions.

Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co‑market a semaglutide injection in India ...

Under the Licensing and Supply Agreement signed by both companies, Lupin will have semi-exclusive rights to co-market Zydus’ ...

Global pharma major Lupin Limited (Lupin) has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited ...

Add Yahoo as a preferred source to see more of our stories on Google. First conceived by the manga artist Monkey Punch (aka Katō Kazuhiko) in 1967, the impish and uncatchable gentleman thief Lupin the ...

Zydus Lifesciences and Lupin have partnered to co-market Semaglutide Injection, a weight-loss medication, in India ...

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to ...

Lupin and Zydus partner to co-market semaglutide in India, entering a Rs 1,200 crore market with over 20 competitors and rapidly commoditising pricing dynamics.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to ...

On Friday, a post on the official X (formerly Twitter) account for the Lupin the 3rd franchise announced a new animated movie set to come out next year. The film, tentatively titled Lupin the IIIrd ...

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping ...